S

Spectrum Pharmaceuticals Inc
F:NTR

Watchlist Manager
Spectrum Pharmaceuticals Inc
F:NTR
Watchlist
Price: 0.925 EUR Market Closed
Market Cap: 189.9m EUR

Relative Value

There is not enough data to reliably calculate the relative value of NTR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NTR Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
8
Median 5Y
7.7
Industry
7.9
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.1
Industry
23.7
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.3
Industry
22
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.3
Industry
24.3
vs History
vs Industry
Median 3Y
7.7
Median 5Y
7.3
Industry
3.3
vs History
vs Industry
Median 3Y
7
Median 5Y
6.6
Industry
8.2
vs History
vs Industry
Median 3Y
7.8
Median 5Y
7.4
Industry
10.2
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.7
Industry
6.1
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.7
Industry
6.5
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
7.9
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
6.3
vs History
vs Industry
Median 3Y
8.6
Median 5Y
8.2
Industry
5.7

Multiples Across Competitors

NTR Competitors Multiples
Spectrum Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Spectrum Pharmaceuticals Inc
F:NTR
189.9m EUR 8.7 -3.4 -3.1 -3.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 667 065.8 -160 014.6 -194 308.7 -192 091.4
US
Abbvie Inc
NYSE:ABBV
406.5B USD 6.8 173.1 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.1B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
154.9B USD 5.3 19.1 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 092.5 -534 -581.4 -565.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD 5.8 18.1 17.3 19.6
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD 16.4 1 211.8 163.4 198.2
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.2 59.8
P/E Multiple
Earnings Growth PEG
US
S
Spectrum Pharmaceuticals Inc
F:NTR
Average P/E: 191.5
Negative Multiple: -3.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 014.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 211.8
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
S
Spectrum Pharmaceuticals Inc
F:NTR
Average EV/EBITDA: 40.4
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 308.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
11%
1.6
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.4
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
S
Spectrum Pharmaceuticals Inc
F:NTR
Average EV/EBIT: 46.6
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 091.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.6
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.2
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A